News
12 May 2026
Frost & Sullivan’s 2026 Global Company of the Year
Frost & Sullivan is pleased to announce that Avance Clinical has been awarded the 2026 Global Company of the Year Recognition in the biotechnology contract research organization (CRO) industry for its outstanding achievements in innovation, strategy execution, and customer impact.
2 March 2022
Brett Favre Talks Concussion
Listen to football legend Brett Favre on 5AA ‘Rowey’s Sports Show’ talk about concussion in sport and the therapy that leading biotech firm Odyssey Health as in clinical trials with Australia’s CRO Avance Clinical.
14 February 2022
Avance Clinical Announces New Office Opening in Sydney
Avance Clinical, the largest premium Australian Contract Research Organization (CRO) for international biotechs, has opened new offices in Sydney to support its growing clinical team in the greater Sydney region.
25 November 2021
Avance Clinical Featured in Endpoints News on Cell & Gene Therapy Capabilities
The cell and gene therapies (CGT) sector offers unprecedented opportunities for patient disease management across virtually all therapeutic areas.
23 October 2021
Avance Clinical Featured in Fierce Biotech on Intranasal Expertise
With the global intranasal drug delivery market estimated to reach up to $71 billion over the next five years, Avance Clinical is seeing an increase in biotech clinical trials targeting this growing market demand.
18 October 2021
XWPharma Initiates First-in-Human Studies of XW10508, in Development for Fast-acting Relief of Treatment-Resistant Depression and Chronic Pain
Avance Clinical's client XWPharma Ltd. has announced dosing of subjects in its first-in-human study evaluating XW10508, the Company’s novel, patented, glutamatergic NMDA antagonist and AMPA activator in development as an oral, once-daily therapy for the treatment of treatment-resistant depression and chronic pain.
10 August 2021
Avance Clinical Awarded Frost & Sullivan 2021 Asia-Pacific CRO Best Practices Award for Customer Value Leadership
Avance Clinical has been awarded the prestigious Frost & Sullivan 2021 Asia-Pacific CRO Customer Value Leadership Award, the second consecutive Asia-Pacific (APAC) CRO Best Practices Award for the company from Frost & Sullivan.
9 July 2021
XWPharma Announces Positive Results from Phase 1 Clinical Trials of XW10172, in Development as Once-Nightly Therapy for Sleep Disorders in Patients with Neurodegenerative Diseases
The leading Australian CRO for international biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical today congratulated client XWPharma on receiving positive results from its Phase 1 clinical trial of XW10172.
9 July 2021
Avance Clinical Congratulates Client Tetherex Pharmaceuticals on Initiation of Dosing in a Phase 1 Clinical Study Using a Novel Single-Cycle Adenovirus Vaccine Strategy in Australia
The largest Australian full-service CRO for international biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner Avance Clinical today congratulated client Tetherex Pharmaceuticals on first patient dosing for its Phase 1 vaccine clinical trial.
2 July 2021
Andy Hu on Avance Clinical – why it is the right CRO for Chinese Biotechs
Business Development Manager APAC, Andy Hu, explains why Avance Clinical is the right CRO for Chinese Biotechs.
24 June 2021
Avance Clinical Announces Appointment of Asia Biotech Specialist to Support APAC Growth
The leading Australian CRO for international biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient Avance Clinical today announced the appointment of APAC expert Andy Hu as Business Development Manager APAC to support increasing biotech clinical trial demand from the region.
20 June 2021
Avance Clinical’s USA Biotech Survey Finds 21% Not Aware Australian Clinical Data is Accepted by the FDA and Other Major Regulatory Authorities
Avance Clinical announced the results of their Australian Clinical Trials Knowledge Survey with Endpoints News as part of their presence at BIO Digital 2021.
10 June 2021
TrialTrove Data Shows Australia is Open for Business says Avance Clinical at BIO Digital 2020
The leading Australian CRO for biotechs, Avance Clinical announced at BIO Digital today that Australia currently has 2,413 trials planned or ongoing.
Proven industry
experience & expertise
500+
Studies in the past 5 years
450+
Experienced team members
18k+
Participants past 5 years
30
Years of CRO experience